Skip to content
Search AI Powered

Latest Stories

First Ever Trial Shows Promise for 'Magic Mushrooms'

First Ever Trial Shows Promise for 'Magic Mushrooms'

[DIGEST: Scientific American, Lancet Psychiatry, Huffington Post]

The first clinical trial to use psilocybin, the active compound in “magic mushrooms,” to treat major depression shows promise in a small but breakthrough study. Researchers from Imperial College London gave psilocybin to 12 people suffering from severe depression. One week after receiving an oral dose of the compound, each participant exhibited significant improvement in symptoms. The study further demonstrated psilocybin’s safety in a supervised setting.


Six men and six women suffering from chronic, treatment-resistant depression took two doses of psilocybin (10 mg and 25 mg) separated by one week. Each participant had experienced major depression for 17.8 years on average and none of them had responded to standard treatment, such as selective serotonin reuptake inhibitors (SSRIs) or electroconvulsive therapy. Three months later, five of the participants were in complete remission. If larger studies confirm these findings, medical professionals treating those who don’t respond to therapy or traditional medications may have a new and powerful tool.

(Credit: Source.)

The study did not have a control group, and the participants received psychological support before, during and after each session. The participants relaxed on a bed and listened to music through earphones during each dosing session. Researchers monitored blood pressure, heart rate, and the compound’s psychoactive effects. For the most part, according to the study, the participants went on their own “inner journey” without interruption or interference. None of the participants required medical intervention due to negative side-effects. Some reported experiencing mild anxiety or nausea. The psychedelic effects of the dosage peaked after two to three hours. Most remarkably, eight of the 12 participants met the criteria for remission from depression one week after the two treatments. Relative to baseline, five participants were in complete remission after three months and two others continued to show improvement.

The results are not without some caveats. The study might be biased, some note, because certain participants

To read more, please continue to page 2.

admitted taking psilocybin at least once before. Past experience with psilocybin and its effects might have increased suggestibility and expectancy in participants, thereby affecting the outcome. Further studies can address these problems through the inclusion of a control group or by conducting a double-blind study, in which any information that may influence the behavior of the tester or the subject is withheld until after the test.

“You cannot conclude from this trial that psilocybin is a treatment for depression because there could be other reasons people responded, including the psychotherapy treatment [that accompanied the experimental treatment] and expectancy biases which can be part of this placebo effect,” says Dr. Stephen Ross, director of the Psychedelic Research Group at NYU Langone Medical Center. Dr. Ross is conducting his own clinical trials on psilocybin’s effects on cancer-related depression.

Robin Carhart-Harris is a neuropsychopharmacologist at Imperial College London and one of the authors of the study. The study, he says, does not suggest that doctors should not use psilocybin as a last resort for their depressed patients. “That is pretty remarkable in the context of currently available treatments,” he said. “Our conclusion is more sober than that—we are simply saying that this is doable. We can give psilocybin to depressed patients, they can tolerate it, and it is safe. This gives us an initial impression of the effectiveness of the treatment.”

Robin Carhart-Harris (Credit: Source.)

However, previous studies have shown that psilocybin could be a viable treatment for anxiety, obsessive-compulsive behavior and addiction. Research suggests psilocybin is not an independent risk factor for mental health problems. Nevertheless, demonstrating the safety of psilocybin in a clinical setting was tricky. “Magic Mushrooms” are a Class A Illegal Drug in the United Kingdom. This is the harshest category, which also includes heroin and cocaine. The ethics committee that granted approval for the trial expressed concern that participants could experience delayed onset psychotic symptoms and requested a three-month follow-up for the volunteers. “Every interaction—applying for licenses, waiting for licenses, receiving the licenses, applying for contracts for drug manufacture, on and on—involved a delay of up to two months. It was enormously frustrating, and most of it was unnecessary,” says neuropsychopharmacologist David Nutt, the study’s main author. “The study result isn’t the remarkable part—it’s the fact that we did it at all.”

Depression is the “leading cause of disability worldwide,” according to the World Health Organization. Researchers looking for alternative treatments have turned to ketamine and ayahuasca, both of which have shown promise in clinical trials. “It’s worth noting that we have not developed any new treatments which are widely used since the 1970s for depression, despite the fact that this is the major public-health problem in the Western world and middle-income countries,” says Glyn Lewis, who studies psychiatric disorders at University College London. Psilocybin is a promising alternative, Lewis notes, because it appears to take effect after a single dose, whereas some current medications for depression must be taken daily.

“This study is simply asking: is this interesting enough to pursue further as a treatment for depression?” says Lewis. “My own judgment is that yes, it is.”

More from News

Linda McMahon
Chip Somodevilla/Getty Images

Hacker Hilariously Trolls Education Secretary With Music Choice At Right-Wing Conference

Education Secretary Linda McMahon was trolled by a hacker who hijacked the sound system and played circus music over remarks she gave during an appearance at a Young America’s Foundation event for conservative youth.

At one point, McMahon was cut off by audio of someone calling her a "corrupt billionaire who knows nothing about education," prompting her to look around nervously.

Keep ReadingShow less
Screenshots from @summermken_official's TikTok video
@summermken_official/TikTok

Woman Goes Viral After Cramming Carry-On Luggage Into Size Checker To Prove It Fits

Let's be honest: traveling, and particularly flying, is very expensive these days, and it's important to save money wherever you can. A key way to save money is to book a cheaper class on the flight, and to only take a carry-on, rather than checking a bag, if you're able to.

TikToker @summermken_official shared a video of a woman who was willing to commit to that while in Paris. She approached a size-checking station for Vueling Airlines with a sign that read, "Does your cabin luggage fit here?" It was a metal frame in the shape of a rectangle, emulating the largest size that a piece of carry-on luggage could be.

Keep ReadingShow less
Alexandria Ocasio-Cortez; Chris Cuomo
Chet Strange/Getty Images; John Lamparski/Getty Images for Tribeca Festival

AOC Rips Chris Cuomo's Non-Apology After He Fell For Deepfake Of Her Criticizing Sydney Sweeney

For anyone wondering what Chris Cuomo has been doing since being fired by CNN in 2021 amidst big brother Andrew Cuomo's sexual harassment scandal, it wasn't learning how to spot deepfakes.

Even when they're watermarked "parody 100% made with AI."

Keep ReadingShow less
Pedro Pascal
Lia Toby/Getty Images

Fans love Pascal's clapbacks

America’s favorite zaddy Pedro Pascal has officially had it with the social media trolls in his comments.

Specifically, the ones obsessing over how physically close he gets to his male and female co-stars—as if basic and consensual human warmth is now suspicious behavior.

Keep ReadingShow less
Serena Williams
ANGELA WEISS/AFP/Getty Images

Fans Jump To Serena Williams' Defense After Gym Selfies Spark Accusations That She's Using Ozempic

Largely because of social media, it's becoming increasingly hard to know what is real, honest, and authentic. This includes people's appearances, weight and physique, and what they did to reach the look they've achieved.

Throughout this summer, people have been commenting on Serena Williams' Instagram posts, accusing her of losing too much weight and even of using Ozempic.

Keep ReadingShow less